Siemens Healthineers and Paradromics Align Imaging Workflow With the Needs of Brain-Computer Interfaces
Paradromics is teaming with Siemens Healthineers to build an advanced multimodal imaging platform for implantable brain-computer interfaces, a move that pushes the field beyond proof-of-concept electronics and into the more complicated business of patient selection, target definition and surgical precision. The collaboration is aimed at the full arc of BCI care, from candidacy assessment to post-implant localization and outcomes evaluation.
The pairing makes sense because BCI success does not begin with the implant itself. It begins with whether the team can see the right anatomy well enough to choose the right patient, the right neural target and the safest trajectory into the brain.
Multimodal Imaging Becomes the Gatekeeper for BCI Placement
The planned workflow brings together structural MRI, functional MRI, vascular imaging and CT. In practical terms, that combination can map anatomy, identify regions tied to speech or motor function, trace blood vessels that must be avoided during surgery and verify where implanted components ultimately sit inside the brain. For a technology class that depends on millimeter-scale accuracy, those details are not peripheral. They are central to whether a device can deliver stable signal capture without damaging adjacent tissue.
Paradromics and Siemens Healthineers intend to convert those imaging steps into an integrated package that includes image acquisition, co-registration, processing, surgical-navigation-ready outputs and increasingly automated analysis. If the workflow performs as intended, it could reduce fragmentation between radiology, neurosurgery and device implantation. In a field where one missed vascular structure or misidentified functional area can alter the surgical plan, a standardized imaging sequence could become as important as the implant hardware itself.
The companies say the approach is designed to be deployable across medical centers using Siemens Healthineers imaging systems. That detail matters for a technology still in the early clinical phase. A BCI platform that can only function in a handful of highly specialized centers will remain limited; one that can be translated into existing imaging infrastructure has a clearer path toward broader clinical use.
Speech-Motor Function Sits at the Center of the First Use Case
The collaboration is expected to focus first on speech-motor function, building on Paradromics’ clinical work in communication restoration. Speech is a demanding target for a BCI because it sits at the intersection of motor planning, language processing and real-time output. Imaging that can localize functionally relevant regions before surgery may help investigators identify the neural territory most likely to support communication restoration while minimizing avoidable risk.
Matt Angle, PhD, Paradromics’ founder and CEO, framed the effort as part of a larger pre-implant strategy. Building better hardware is only part of the story, he said, because BCI performance begins before an implant ever reaches the brain. He emphasized that understanding each patient’s anatomy and functional organization may help identify the right neural target and improve placement accuracy.
That is not just a technical refinement. It is a biological necessity. BCIs depend on clean neural signal acquisition, and clean signals are harder to obtain when electrodes are positioned too far from the intended cortical region or when the surrounding anatomy is not fully characterized before surgery. Functional imaging can help define where language- or motor-linked activity is likely to be represented, while vascular imaging lowers the chance of collateral injury during implantation.
The Imaging Stack Could Shape More Than One Neurologic Indication
Paradromics and Siemens Healthineers are also looking beyond the initial communication-focused use case. The companies envision extending the approach to additional BCI applications, including hand motor control and language restoration after stroke. Those expansions are clinically meaningful because post-stroke patients often present with complex patterns of injury, residual function and network reorganization that make preoperative imaging especially valuable.
Stroke-related language deficits are not simple loss-of-function states. They often involve distributed damage across cortex and subcortical networks, which makes a high-resolution structural and functional map useful not only for placement but also for understanding what signal pathways remain viable. A BCI workflow built for that level of complexity could support more individualized intervention planning than a one-size-fits-all surgical template.
The same logic applies to hand motor control. Neural areas that govern fine motor activity can be anatomically close to critical vascular structures and other eloquent cortex. An imaging platform that supports precise co-registration and navigation may help teams approach those targets with greater confidence.
What the Partnership Says About the Next Phase of BCI Development
The broader significance of the agreement lies in what it reveals about the maturation of brain-computer interface care. Early BCI work often focused on whether implants could translate thought into action at all. The current challenge is more operational: how to place them safely, how to predict which patients are best suited for them and how to confirm that the implant is functioning in the intended neural region after surgery.
Siemens Healthineers brings imaging depth to a field that increasingly needs more than signal processing and implant design. Paradromics brings clinical and technical experience specific to BCIs. Together, the companies are trying to formalize a workflow around questions that are now central to bedside implementation: where the implant should go, how to get there safely and how to document whether the result matches the intended neuroanatomy.
That approach also reflects an important shift in expectations. A successful BCI is no longer defined solely by whether it can produce a usable output in the lab. It must also fit into existing hospital systems, support surgical teams, and generate interpretable post-implant data that can guide follow-up care. Imaging sits inside every one of those steps.
The collaboration stops short of providing performance data, regulatory milestones or timeline details. It also does not establish whether this imaging platform will ultimately alter patient selection, surgical outcomes or long-term BCI durability in practice. Those questions remain open, and the clinical value of the workflow will depend on whether it improves accuracy and consistency once it is tested in real patients rather than in concept alone.